Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

INTRODUCTION: CAR T-cell therapy has emerged as a promising new immuno-oncology treatment that engages the patient’s immune system to fight certain hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). In the European Union (EU), CAR T-cell therapies have been approved for rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Canales Albendea, Miguel Á., Canonico, Pier Luigi, Cartron, Guillaume, Deiters, Barthold, Jommi, Claudio, Marks, Reinhard, Rioufol, Catherine, Sancho Cia, Juan M., Santoro, Armando, Wagner-Drouet, Eva M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263061/
https://www.ncbi.nlm.nih.gov/pubmed/37324138
http://dx.doi.org/10.3389/fmed.2023.1128295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263061/
https://www.ncbi.nlm.nih.gov/pubmed/37324138
http://dx.doi.org/10.3389/fmed.2023.1128295

Ejemplares similares